🇺🇸

US SEC Filing Intelligence

Daily AI-powered analysis of SEC EDGAR filings, FDA approvals, and US regulatory disclosures. Investment signals, risk flags, and sector themes for US markets.

·daily

S&P 500 Healthcare Sector SEC Filings — March 30, 2026

Across 48 SEC filings from the USA S&P 500 Healthcare stream (primarily biotech, pharma, med devices amid broader financials), dominant themes include robust M&A activity (BSX-Penumbra merger, Aurinia-Kezar acquisition) and FDA catalysts (Unicycive OLC PDUFA June 29, 2026), with mixed FY2025 financials showing 6/10 biotechs narrowing net losses YoY (avg -25%, e.g., Unicycive -28% to $26.6M) but rising G&A/R&D expenses averaging +40%. Period-over-period trends reveal healthcare innovators extending cash runways into 2027 (Unicycive $54.9M, Aura $144.2M) despite no revenues, contrasting with deteriorations like Ensysce net loss widening 28% to $10.2M and Interpace PancraGEN discontinuation post-CMS loss. Capital allocation leans toward equity raises (Artelo $11M private placement) and buybacks (News Corp $1B program), while non-healthcare filings (e.g., CIM REIT portfolio -1.6% YoY) dilute focus but highlight relative biotech resilience. Critical developments like Sight Sciences $34M patent win and ProCap merger approval signal upside, but risks from delistings (Interpace, Zivo) and going concerns (CISO) warrant caution. Portfolio-level, healthcare shows +9% avg revenue growth in reporting firms (CareView +9%) with margin stabilization, positioning for H2 2026 catalysts amid sector M&A premiums.

29 high priority19 medium48 total filings
·daily

US Executive Compensation Proxy SEC Filings — March 30, 2026

Across 34 DEF 14A proxy statements filed around March 30, 2026, a dominant theme is robust 2025 performance with 12 companies reporting double-digit revenue growth (avg 10% YoY, e.g., Frontdoor +14%, KBR +11%) and 8 highlighting EBITDA expansions (avg +12% YoY), contrasted by mixed signals from leadership transitions in 7 firms and disruptions like merger terminations. Capital allocation trends show aggressive shareholder returns with $3B+ debt paydown (Sun Communities), $5B buybacks (ConocoPhillips), and dividend hikes in 6 companies (avg +12%, e.g., Patrick +17.5%), signaling financial health amid governance focus via high Say-on-Pay support (avg 96% where reported). Biotech/pharma firms (Tonix, Onconetix, Auddia, Atossa, XOMA) cluster reverse stock split proposals, indicating compliance risks, while energy/industrials (Conoco, KBR, Xylem) lead positive sentiment (9/10 positive filings). Portfolio-level, margins expanded in 6/10 with operational metrics (e.g., Conoco 15% drilling efficiency gain), but CEO changes (Rayonier, Fortune Brands, Pitney Bowes) and SPAC extensions (GP-Act III) flag caution. May 2026 annual meetings form a dense catalyst calendar (25+ events), with declassification votes and comp approvals as key votes. Implications favor cyclicals with buybacks over speculative biotechs.

34 high priority34 total filings
·daily

US IPO Pipeline SEC S-1 Filings — March 30, 2026

The IPO Pipeline stream features two SEC filings on March 30, 2026: Cadre Holdings' S-4 shelf registration for up to 7,500,000 shares to fund future acquisitions and Elmet Group Co.'s S-1 for its initial public offering on Nasdaq under 'ELMT'. No period-over-period financial comparisons are available, as Elmet's preliminary prospectus explicitly provides no financial performance data and Cadre's filing focuses on share registration without operational metrics. Neutral sentiment prevails across both, with Elmet carrying higher materiality (10/10) due to its IPO status as an emerging growth and smaller reporting company in fabricated metal products. Cadre signals proactive M&A strategy in safety equipment markets, while Elmet highlights speculative high-risk entry into public markets post-reorganization on January 2, 2026. Portfolio-level pattern: Early-stage capital market preparations amid neutral outlook, with no YoY/QoQ trends but potential for new listings and dilution. Market implications include monitoring for IPO catalysts and acquisition targets, positioning investors for alpha in industrials.

2 high priority2 total filings
·daily

Global High-Priority Regulatory Events — March 30, 2026

Across 50 filings from March 30, 2026, focused on global high-priority events, dominant themes include SPAC mergers advancing toward imminent closings, heavy promoter encumbrances and pledge releases in Indian firms signaling liquidity pressures, mixed 10-K results with revenue surges (e.g., OneMedNet +111% YoY) offset by widening losses and impairments (e.g., Origin Materials -40% revenue, $196M impairment), and biotech financings amid going concern warnings. Period-over-period trends reveal 8/15 10-K filers with revenue growth averaging +85% YoY but losses expanding in 10/15 (avg +150%), driven by expense spikes and asset write-downs, while capital raises ($150M OnKure, $750M Ingevity revolver) bolster balance sheets. Critical developments like Vine Hill's 92.6% merger approval (closing Mar 31), IL&FS bond default, and IndusInd SFIO probe heighten volatility risks. Portfolio-level patterns show crypto/AI names with asset growth but volatility (AIxCrypto assets +568% YoY), shipping/energy facing covenant pressures, and Indian banks/pharma with encumbrance fluctuations (e.g., IndusInd promoters to 0% encumbered). Implications favor short-term trading around catalysts like Mar 31 closings and May AGMs, with caution on insolvencies and Nasdaq deficiencies.

50 high priority50 total filings
·daily

US Earnings Financial Results SEC Filings — March 30, 2026

Across 50 10-K and 10-Q filings from March 30, 2026, primarily small-cap biotechs, SPACs, crypto/AI firms, and financial trusts, sentiment is mixed (70% of filings), with 18 companies narrowing net losses YoY (avg improvement 40%, e.g., OneMedNet -72%, ImmuCell -52%) amid revenue volatility: 14 firms grew revenue (avg +95% YoY, outlier OneMedNet +111%), 13 declined (avg -18%, e.g., Soluna -22%, Origin -40%). Biotechs (12 filings) show R&D cuts in 6 but persistent cash burn (avg op cash use +15%), while SPACs (12) hold trust assets ($10B+ aggregate) but report deficits and no combinations. Crypto firms (5) post impairments ($40M+) offset by financing ($150M+ inflows). Capital allocation leans to financing raises ($1B+ aggregate) over dividends/buybacks; no insider trades noted, but 8 firms flag going concerns. Portfolio implications: Selective opportunities in turnarounds like Galaxy Gaming (profitability flip), risks in high-burn biotechs and pre-IPO SPACs; sector rotation toward profitable niches like banks (GBank NI +12%).

50 high priority50 total filings
·daily

US SEC Trading Suspension Halt Orders — March 30, 2026

Across 7 US-listed companies facing trading suspensions or delisting risks in late March 2026, themes center on Nasdaq $1 minimum bid price violations (4/7 filings), financial metric deficiencies (2/7), and one voluntary delist post-SPAC merger, highlighting small-cap liquidity and compliance struggles. Positive resolutions emerged in Vine Hill Capital's 92.6% merger approval leading to relisting as Odysseus, Sky Quarry's post-reverse-split compliance regain, and Triller's conditional reinstatement path, contrasting with ongoing risks for Dyadic, Greenlane, InMed, and Skillsoft. No explicit YoY/QoQ financial trends available, but repeated non-compliance periods (e.g., Sky Quarry's two 180-day extensions expiring Sep 2025/Mar 2026) signal deteriorating bid prices over 12+ months. Mixed sentiment prevails (3 negative, 2 mixed, 1 positive, 1 negative on NYSE), with materiality high (8-10/10), implying imminent trading halts or delistings for non-compliant firms, pressuring valuations and liquidity. Portfolio-level pattern: reverse splits in 3/7 (Sky Quarry 1:8, Greenlane cumulative 1:8250) as desperate compliance tools, often failing long-term. Market implication: short-term volatility spikes around Mar 31 deadlines, potential OTC trading shifts reducing institutional access.

7 high priority7 total filings
·daily

US Corporate Distress Financial Stress SEC Filings — March 30, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream (Mar 30, 2026 period), proactive liquidity management dominates with 25+ credit amendments/extensions/increases (e.g., Nexstar $1.75B Term B-7, Ares $350M facility to $400M accordion) signaling lender support amid distress risks. True distress limited to 1 Chapter 11 (Twin Hospitality governance overhaul), 7 Nasdaq/NYSE deficiencies/delisting threats (Dyadic equity <$2.5M, Greenlane post-multiple reverses), and reverse splits (agilon 1:25, Safe & Green 1:20). Positive asset sales for cash (Spire $215M gas marketing, Star Equity $1.69M properties) and equity raises (OnKure $150M, Capstone $112.5M) outpace negatives. No broad YoY/QoQ declines reported, but Spire cut FY27 EPS guidance to $5.40-$5.60 from $5.65-$5.85 despite FY26 affirm. Sentiment: 20 positive, 15 neutral/mixed, 8 negative; portfolio trend shows contained distress via refinancing, but small-cap Nasdaq risks elevated. Implications: Favor companies completing financings (e.g., closings 3/31/26) over compliance-challenged names.

50 high priority50 total filings
·daily

US Executive Officer Management Changes SEC — March 30, 2026

Across 35 SEC filings from March 26-30, 2026, focused on US executive and director changes, a high volume of leadership transitions signals potential strategic realignments amid economic pressures, with 15+ appointments, 12 resignations/retirements, and several interim roles in healthcare/biotech (12 filings), industrials, and tech sectors. Positive themes include experienced hires (e.g., Teladoc's Susan Salka with $5B revenue growth track record) and CEO sacrifices (Rocket Lab's Peter Beck forfeiting 392k RSUs and slashing salary to $1), contrasting risks from discord-driven exits (Ensysce director resignation over severance disputes) and sudden terminations (Newton Golf CEO). No broad YoY/QoQ financial declines noted, but reaffirmed guidance (Inogen Q1/FY2026), performance-tied incentives (UHS 150% CEO bonus target on adj. EPS/ROC), and salary hikes (Graham CEO to $600k, + undisclosed prior) indicate focus on growth incentives over cuts. Capital allocation leans toward equity incentives (RSUs/PBRSUs in 8 filings) vs buybacks/dividends. Portfolio implication: Healthcare shows churn (e.g., Tenet, Entergy transitions) but positive hires; small caps like biotechs exhibit instability (5 resignations), urging caution on execution risks while opportunities arise from undervalued turnarounds with strong interim leadership.

35 high priority35 total filings
·daily

US Corporate Board Director Changes SEC Filings — March 30, 2026

Across 35 SEC filings on USA Board Room Changes dated March 30, 2026, there is elevated executive and board turnover with 18 resignations/departures (e.g., CEOs, CFOs, directors) and 22 appointments/promotions, signaling potential strategic shifts amid neutral-to-positive sentiment in 70% of cases. Healthcare/biotech dominates (12/35 filings) with experienced hires like Susan Salka at Teladoc and Bill Gassen at HealthEquity, while finance roles see frequent transitions (e.g., Entergy Texas, Tenet, Commerce Bancshares). No broad period-over-period financial declines noted, but Inogen reaffirmed Q1/FY2026 guidance post-CFO change, and SunPower secured strong shareholder approval (>66M votes) for equity expansions amid mixed sentiment. Key themes include internal promotions for continuity (e.g., Cross Country, Trustmark) and pay adjustments for capital preservation (Rocket Lab CEO salary to $1). Portfolio-level pattern: 8/12 healthcare filings bullish on growth expertise additions vs. isolated discord (Ensysce). Implications: Bullish for turnaround plays with proven hires, cautious on sudden C-suite exits signaling execution risks; monitor Q2 catalysts like retirements and annual meetings.

35 high priority35 total filings
·daily

US Merger & Acquisition SEC Filings — March 30, 2026

The March 30, 2026, filings reveal heightened USA M&A and takeover activity, with 4 major acquisitions/divestitures (Leidos $2.4B, Addentax control stake, Bitmine blockchain assets, Aimco $455M property sale) signaling strategic expansion in energy infrastructure, fashion, crypto staking, and REIT portfolio optimization. SPACs dominate the rest, with extensions (Constellation to April 29), redemptions (ASPAC shares down 71% YoY post-Oct), resignations (UY Scuti CFO), and voting (Relativity), reflecting ongoing deal pursuits amid deadline pressures. Positive sentiment prevails in 4/8 filings (50%), mixed in Aimco due to pro forma revenue decline 33% to $92.6M for 2025 despite liquidity boost (cash +$547.5M, debt -to $457.3M). No insider trading or dividend changes noted across filings, but transaction terms highlight deferred payments/earnouts (Bitmine $14M deferred + $11.8M earnout). Portfolio trend: Acquirers gaining scale (Leidos doubling energy presence), SPACs managing liquidity for catalysts; watch SPAC merger votes for takeover upside.

8 high priority8 total filings
·monthly

US Pre-Market SEC Filings Roundup — March 30, 2026

Across 50 overnight SEC filings, dominant themes include mixed financial results in 10-Ks with revenue growth in 6/15 reporting companies (avg +60% YoY outliers like General Enterprise Ventures +195%) offset by widening losses (e.g., Picard Medical net loss +28%, Origin Materials -198%) and impairments; SPACs (8 filings) universally show no revenue, cash burn, and going concern doubts. Biotech sector shines with positive trial data (Alumis Phase 3 success) and funding ($150M OnKure), while energy (ConocoPhillips +15% drilling efficiency) and aviation (Embraer +18.5% revenue) report strength amid margin pressures. Capital allocation leans toward buybacks (News Corp $1B program) and dividends (steady in Presidio, Cottonwood), but debt issuances/amendments (Amphenol, Nexstar $1.75B) signal leverage. Forward-looking catalysts cluster in H2 2026 (NDAs, pilots, data readouts), with M&A momentum (RYVYL, Volato). Portfolio-level: Margin compression avg -50bps in 7/10-Ks, cash surges via financing in 5 firms (Soluna +$68M), but Nasdaq deficiencies and going concerns flag 4 high-risk names. Implications: Tactical buys in biotech/energy catalysts, caution on microcaps/SPACs pre-market.

38 high priority12 medium50 total filings
·daily

S&P 500 Technology Sector SEC Filings — March 27, 2026

Across 25 SEC filings in the USA S&P 500 Technology stream (despite diverse sectors), proxy season dominates with 12+ DEF 14A/DEFA14A filings for May 2026 annual meetings (AMD May 13, Murphy Oil May 13, CBU May 20, TSQ May 11, CPT), highlighting governance, comp approvals, and equity plans amid mixed financial trends. Period-over-period data shows growth outliers like Community Financial System's 9.7% YoY revenue increase (+$72.1M), 15.4% diluted EPS growth, and Murphy Oil's 3% production rise to 182 MBOEPD with 20% LOE/BOE reduction, contrasted by declines such as Muzinich BDC's 28% YoY investment income drop to $17.1M and AIM ImmunoTech's $82k revenue decrease with halted sales. Tech-specific signals include AMD's proposed +65M share equity plan, Planet Labs' full warrant redemption reducing dilution, and BlockchAIn Digital Infrastructure's $500M+ AI data center LOIs. Capital allocation trends favor shareholder returns (Murphy $286M, CBU 2.2% dividend hike for 33rd year), with auditor changes routine (Sun Communities, Portsmouth Square). No clustered insider trading, but forward-looking catalysts like AIB's webinar and exec transitions (SBA retirement Dec 2026) point to monitoring AI infra demand and governance votes. Portfolio implications: Selective bullishness in growth proxies/AI, caution on income declines/supply risks.

14 high priority11 medium25 total filings
·daily

Nasdaq 100 Stocks SEC Filings — March 27, 2026

Across 32 filings from NASDAQ-100 constituents and related names, proxy season dominates with 15+ DEF/DEFA14A filings announcing May 2026 annual meetings, signaling routine governance but highlighting dividend growth (e.g., PepsiCo's 54th consecutive increase) and board refreshes. Period-over-period trends show mixed financial health: bullish growth in select names like Murphy Oil (production +3% YoY to 182 MBOEPD, LOE/BOE -20% to $10.89) and Community Financial System (revenues +9.7% YoY, EPS +15.4%), contrasted by widening losses in TMC the metals (-150% YoY Q4 net loss to $40.4M) and Muzinich BDC (investment income -28% YoY). Capital allocation leans shareholder-friendly with PepsiCo and Community boosting dividends, while operational risks persist in biotech (AIM ImmunoTech halted sales) and metals (TMC permitting delays). Vanguard's 13G/A amendments across Netflix, MSFT, PYPL, TSLA, WMG reflect passive realignments with no ownership shifts, maintaining stability in mega-caps. Portfolio-level, energy/financials outperform (avg +10% YoY metrics) vs metals/biotech underperformance (-20% avg), with May meetings as key catalysts for compensation votes and auditor ratifications. Implications: Favor dividend growers amid volatility, monitor biotech/metal turnarounds.

17 high priority15 medium32 total filings
·daily

S&P 500 Financials Sector SEC Filings — March 27, 2026

Across 50 diverse SEC filings from the USA S&P 500 Financials intelligence stream (including banks, REITs, insurers alongside adjacent sectors), key themes include heightened M&A and restructuring activity (e.g., mergers at Two Harbors, Dillard's, Allegiant), routine proxy season launches with neutral sentiment, and mixed financial results showing revenue growth in 12/50 filings (avg +25% YoY where reported, e.g., Worthington +24%, Legence +34.6% Q4) but widening losses in biotechs/miners (e.g., TMC FY loss +290% YoY to $320M). Period-over-period trends reveal organic sales expansion (Worthington +14%) offset by margin compression (Worthington gross margin -40 bps, Legence Q4 -60 bps) and credit deterioration in financials (Avidia Bancorp charge-offs $21M, nonaccruals +406% YoY). Forward-looking catalysts cluster in H1 2026: spin-offs (AnaptysBio Apr 20), AGMs (May cluster), compliance plans (BiomX Apr 24), and raised guidances (Legence FY26 rev $3.7-3.9B, +42% midpoint YoY). Capital allocation leans shareholder-friendly with buybacks (Carnival $2.5B), dividends (Blue Owl monthly $0.0748/share), and refinancings (Delek Logistics new credit facility), but no broad insider trading patterns emerge. Portfolio implications: overweight M&A targets for near-term premiums, monitor bank credit risks amid NIM expansion (Avidia +40 bps to 3.29%), and favor revenue growers with liquidity buffers (Kailera $546M cash/secs). Overall sentiment mixed/neutral (32/50), with 10/50 positive on growth catalysts.

27 high priority23 medium50 total filings
·daily

S&P 500 Consumer Staples Sector SEC Filings — March 27, 2026

Across 50 diverse SEC filings (primarily proxies, 8-Ks, and 10-Ks, with limited true S&P 500 Consumer Staples representation like PEP, HAIN, MNST), proxy season dominates with 10+ annual/virtual meetings clustered in May 2026 (e.g., PEP May 6, F May 14, MNST May 14), signaling routine governance but opportunities in dividend votes and board refreshes. Period-over-period trends reveal revenue growth in outliers (Aurora Mobile +19% YoY to RMB 375M, MicroCloud +39% YoY to RMB 404M, Lifeloc +6% to $9M) but widespread declines in commodity funds (US Oil Fund assets -25.8% YoY to $37M, US NatGas -1.2% to $19M) and product revenues (Kopin -42% YoY to $8.4M); margins stable/flat in Lifeloc (40.3%) but implied compression in MicroCloud (~21% from 23%). Capital allocation highlights PEP's 54th consecutive dividend hike (June 2026 payment); forward-looking catalysts include drug sNDAs (BioXcel YE2026), Phase 3 readouts (Kodiak), and M&A (Clear Channel merger post-go-shop). Risks cluster around listing deficiencies (HAIN, Alight < $1 bids) and cyber incidents (CareCloud); portfolio-level theme: resilient servicing in 12+ Exeter ABS trusts but sector mismatches dilute staples focus, implying broader market stability amid energy/biotech volatility.

31 high priority19 medium50 total filings
·daily

S&P 500 Industrials Sector SEC Filings — March 27, 2026

Across 50 filings from S&P 500 Industrials and related sectors, proxy statements dominate (e.g., DEF 14A/DEFA14A for Marriott, Murphy Oil, Aspen Aerogels, 3M, Norfolk Southern, Ampco-Pittsburgh, Camden), signaling routine governance with neutral sentiment but highlighting board changes and upcoming AGMs in May 2026. Financial results show mixed trends: strong revenue growth in industrials like Legence (+21.5% FY2025 to $2.6B, +34.6% Q4) contrasts with declines in tech-adjacent like Luminar (-12% YoY revenue to $66M), Phunware (-19.9% to $2.6M), and Ideal Power (-56% to $38k), while banks/financials like Avidia report net losses from credit deterioration (nonaccruals +406% YoY to $20M). M&A activity is bullish with Great Lakes Dredge tender at $17/share, Bank of Nagoya MOU for 2028 integration (synergies in assets ¥22T combined), and tuck-ins like Legence's Bowers Group. Capital returns strong at Banco Santander (EUR 3.5B dividends, share cancellations) and Murphy Oil ($286M free cash flow returned). Forward guidance positive for Legence (FY2026 rev $3.7-3.9B, up from prior), Aspen (Q1 2026 $38M settlement, 2027-2028 contracts), but risks from legal overhangs in student loan trusts and NYSE delisting warning for Alight. Portfolio-level: Industrials show resilient backlog growth (Legence +49% to $3.7B) amid margin pressures (Q4 gross margin -60bps to 20%), with catalysts clustered in May AGMs.

34 high priority16 medium50 total filings
·daily

S&P 500 Energy Sector SEC Filings — March 27, 2026

Across the 7 filings in the USA S&P 500 Energy intelligence stream, proxy statements dominate (4/7 filings for Ampco Pittsburgh and EOG Resources), signaling the start of 2026 proxy season with neutral sentiment and unanimous board recommendations FOR director elections, say-on-pay votes, and auditor ratifications at AGMs on May 8 (Ampco) and May 20 (EOG). Knightscope's FY2025 10-K provides the only substantive financials, revealing 5% YoY revenue growth to $11.3M (services +7% to $8.0M, products +1% to $3.4M) but sharply deteriorating gross margins to -42% from -34% (-800bps), operating loss expansion to $33.9M driven by 77% R&D surge to $12.5M, and net loss to $33.8M (+6.5% YoY), offset by cash build to $20.6M via $42.2M financing (+22% YoY). Hallador Energy reported a contestable MSHA imminent danger order at Oaktown Mine with no injuries or production halt (mixed sentiment), while Stoke Therapeutics completed a clean auditor switch to EY for FY2026 (neutral). No insider trading, M&A, or capital allocation details emerged; forward-looking focuses on 2026 auditors and AGMs. Sector themes include governance routine amid isolated profitability erosion and regulatory watch items, implying neutral portfolio positioning with low materiality (avg 6.4/10) but actionable AGM catalysts.

3 high priority4 medium7 total filings
·daily

US Material Events SEC 8-K Filings — March 27, 2026

Across the 50 US SEC filings from March 27, 2026, the dominant themes are widespread executive and board transitions (observed in 25+ filings, including 10+ CEO/CFO changes and 15+ director resignations/appointments), robust financing and refinancing activities (16 instances, including $1.5B+ facilities and $500M+ debt/equity raises), and select M&A/spin-off developments amid neutral-to-positive sentiment (avg materiality 7/10). No explicit aggregate YoY/QoQ financial trends are detailed, but implied liquidity enhancements via new credit lines (e.g., Delek, Enterprise, News Corp) and equity facilities (Cyber Enviro-Tech $30M, LM Funding $75M) signal proactive capital allocation for growth/reinvestment over dividends/buybacks. Critical developments include AnaptysBio's value-unlocking spin-off (April 20 distribution), Two Harbors' $10.80/share merger (H2 2026 close), and Iterum Therapeutics' liquidation petition (hearing April 13)—flagging biotech distress vs. sector resilience. Portfolio-level patterns show shipping/energy firms focusing on debt refinancing (positive for stability), SPACs/biotechs with leadership churn (mixed conviction), and cruise/retail with activist-driven board refreshes (Norwegian Cruise). Market implications: heightened M&A catalysts, monitor leadership stability for conviction signals, and favor liquidity-strong names amid potential volatility from transitions.

50 high priority50 total filings
·daily

Dow Jones 30 Stocks SEC Filings — March 27, 2026

Across the 50 filings for USA Dow Jones 30 constituents and related entities, M&A activity dominates with 10+ deals including Two Harbors' $10.80/share cash merger with CrossCountry Mortgage (closing H2 2026), Allegiant Travel's stock+cash acquisition of Sun Country (pro forma 2025 revenues $3.7B), and multiple JFB Construction/XTEND drone mergers highlighting defense synergies. Period-over-period trends show stark bifurcation: explosive revenue growth in digital assets (BitGo +424% YoY to $16.2B) and select financials (Indivior +4% to $1.24B, Adjusted EBITDA +20%), contrasted by declines in industrials/tech (Kopin Q4 revenues -42% YoY, SpringBig FY2025 -7.4%, SBC Medical FY2025 -15%). Positive clinical and defense catalysts (Kodiak Sciences Phase 3 success, XTEND $500M pipeline/$71M backlog) offset proxy-heavy neutral sentiment, with capital allocation favoring buybacks (Indivior $400M authorization) and financings ($30M CETI equity line, $56M Kopin placement). Portfolio-level margin trends mixed (Indivior +500bps to 35%, SBC -3pts to 40%), but overall bullish M&A wave implies sector consolidation; watch H2 2026 closings for blue-chip upside amid volatile growth patterns.

28 high priority22 medium50 total filings
·daily

US SEC Filings Daily Market Digest — March 27, 2026

The March 27, 2026, SEC filings digest reveals a dominant proxy season theme with 15+ DEFA14A/DEF 14A filings for May 2026 AGMs across sectors like airlines (Southwest, Murphy Oil), pharma (Indivior, Nurix), and metals (Trilogy), signaling routine governance but highlighting positive 2025 recaps (e.g., Indivior revenue +4% YoY to $1.24B, Murphy Oil production +3% YoY to 182 MBOEPD). 10-Ks show stark mixed performance: revenue growth in Sportradar (+17% YoY to €1.29B), BitGo (+424% to $16.2B), but declines in Luminar (-12% YoY to $66M), Phunware (-20% YoY to $2.6M), and SpringBig (-7% YoY to $22.8M), with margin expansions in Indivior (+500 bps to 35%) offset by compressions elsewhere. Biotech shines with Kodiak's Phase 3 GLOW2 success and Nurix's 83% ORR, while credit funds (Oaktree, Blue Owl) maintain stable leverage (0.57x-0.82x) and distributions ($0.0748/share monthly). SPACs/blank checks (BHAV, AltEnergy) report IPOs and leadership changes, and capital allocation favors returns (Indivior $400M buyback, News Corp $1B repurchase). Overall, portfolio trends indicate resilient credit/income strategies amid tech/autonomy weakness, with May AGMs as key catalysts for comp votes and auditor ratifications.

28 high priority22 medium50 total filings
← All geographies